piperidine/inflammation

BACKGROUND OF THE INVENTION (a) Field of the Invention This invention relates to 1-[(3- or 4-benzoylphenyl)-lower-alkyl]-[(CH.sub.2).sub.n --N.dbd.B]-substituted-piperidines and analogs thereof, useful as anti-asthmatic, anti-allergic, anti-cholinergic, bronchodilator and anti-inflammatory agents;

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Even more

TECHNICAL FIELD The present invention relates to spiro-piperidine compounds having chemokine receptor antagonism which are useful as medicines, drugs comprising them as the active ingredients, and production methods and use thereof. BACKGROUND OF THE INVENTION Chemokine is known as a basic protein

FIELD OF THE INVENTION This inventions relates to pharmacologically-active, anti-inflammatory compounds, and more specifically to long aliphatic chain esters of selected zwitterionic organic compounds derived from naturally occurring taurine. This invention pertains to novel zwitterionic compounds

TECHNICAL FIELD The present invention relates to a piperidine derivative. More specifically, the present invention relates to (1) a piperidine derivative of formula (I) ##STR00002## (2) a method for the preparation thereof, (3) a composition comprising it as an active ingredient, (4) a compound of

FIELD OF THE INVENTION The invention relates to a series of novel substituted pyridyl piperidine compounds that are useful in the treatment of hyperproliferative diseases such as cancer, as well as inflammatory or degenerative diseases, in mammals. Also encompassed by the present invention is the

FIELD OF THE INVENTION This invention relates to the use of certain piperidine compounds as sodium channel inhibitors and to the treatment of neuropathic pain by the inhibition of sodium channels. Additionally, this invention relates to novel piperidine-based compounds that are useful as sodium

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a national phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/KR2015/009944 filed Sep. 22, 2015, which claims priority to Korean Patent Application No. 10-2014-0126959 filed Sep. 23, 2014. The contents of each

RELATED APPLICATIONS This application is a U.S. national stage application of PCT international application PCT/EP2012/003771, filed on Sep. 7, 2012, which claims the benefit of European application no. 11007796.3, filed on Sep. 26, 2011. The entire contents of the aforementioned applications are

The present invention relates to substituted pyrrolidin-3-yl-alkyl-piperidines, isomers, and pharmaceutically acceptable salts thereof (herein also referred to as compounds or compounds of formula (1)) and processes for preparation of the same. It is an object of the present invention, therefore, to

The present invention relates to substituted pyrrolidin-3-yl-alkyl-piperidines, isomers, and pharmaceutically acceptable salts thereof (herein also referred to as compounds or compounds of formula (1)) and processes for preparation of the same. It is an object of the present invention, therefore, to

The present invention relates to substituted pyrrolidin-3-yl-alkyl-piperidines, isomers, and pharmaceutically acceptable salts thereof (herein also referred to as compounds or compounds of formula (1)) and processes for preparation of the same. It is an object of the present invention, therefore, to

The present invention relates to substituted pyrrolidin-3-yl-alkyl-piperidines, isomers, and pharmaceutically acceptable salts thereof (herein also referred to as compounds or compounds of formula (1)) and processes for preparation of the same. It is an object of the present invention, therefore, to

The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of

BACKGROUND Compounds such as 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-dione (Formula A) and 3-(2,5-di-methyl-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-dione (Formula B) and other derivatives in this family are currently being studied as anti-proliferative, immunomodulatory, and